{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:32Z","timestamp":1778889752128,"version":"3.51.4"},"reference-count":58,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Plasmablastic lymphoma is a rare subtype of large B-cell lymphoma characterised by an aggressive clinical course with frequent relapses and refractoriness to chemotherapy. It is usually associated with HIV, however, it can also be seen in immunocompetent patients. It has distinct pathological characteristics, such as plasmablastic morphology and lack of CD20 expression. These characteristics pose a clinical and pathological challenge. There is no standard of care established in this entity. In this case report, we described a novel bortezomib-based plasma cell targeted regimen in a HIV-negative patient refractory to chemotherapy.<\/jats:p>","DOI":"10.3390\/curroncol29070399","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T03:41:33Z","timestamp":1658115693000},"page":"5042-5053","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed\/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-5771","authenticated-orcid":false,"given":"Waleed","family":"Sabry","sequence":"first","affiliation":[{"name":"Saskatoon Cancer Centre, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruthi Ganeshappa","family":"Kodad","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/hupa.2002.124723","article-title":"AIDS-related non-Hodgkin\u2019s lymphomas: From pathology and molecular pathogenesis to treatment","volume":"33","author":"Carbone","year":"2002","journal-title":"Hum. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/BLCTT.S142814","article-title":"Plasmablastic lymphoma: Current perspectives","volume":"8","author":"Lopez","year":"2018","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":"Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles","volume":"18","author":"Vega","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2016-0232-RA","article-title":"Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis","volume":"140","author":"Harmon","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.6004\/jnccn.2016.0023","article-title":"Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology","volume":"14","author":"Zelenetz","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12185-016-2082-3","article-title":"Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: Analysis of 24 cases","volume":"104","author":"Koizumi","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"key":"ref_10","unstructured":"Bhatt, R., and Desai, S. (2022). Plasmablastic Lymphoma, StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.semdp.2021.03.006","article-title":"Update on B-cell lymphoproliferative disorders of the gastrointestinal tract","volume":"38","author":"Plummer","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e002097","DOI":"10.1136\/jitc-2020-002097","article-title":"Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin\u2019s lymphoma","volume":"9","author":"Lurain","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e24498","DOI":"10.1097\/MD.0000000000024498","article-title":"Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: A case report","volume":"100","author":"Rong","year":"2021","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: Analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: Poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic lymphoma among human immunodeficiency virus-positive patients: Results of a single center\u2019s experience","volume":"56","author":"Cattaneo","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1200\/JCO.2003.06.039","article-title":"High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy","volume":"21","author":"Re","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/or.2015.3808","article-title":"Human immunodeficiency virus-negative plasmablastic lymphoma: A comprehensive analysis of 114 cases","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1182\/blood-2009-06-229666","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: Yes, we can","volume":"114","author":"Hamadani","year":"2009","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic cell transplantation for plasmablastic lymphoma: A review","volume":"20","author":"Castillo","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2015.12.008","article-title":"Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review","volume":"16","author":"Pinnix","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2020.55.1.49","article-title":"HIV-negative plasmablastic lymphoma: Report of 8 cases and a comprehensive review of 394 published cases","volume":"55","author":"Li","year":"2020","journal-title":"Blood Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00277-017-3109-4","article-title":"Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma","volume":"96","author":"Phipps","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.joms.2005.12.039","article-title":"Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: A case report","volume":"65","author":"Armstrong","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10428190290006260","article-title":"Regression of a plasmblastic lymphoma in a patient with HIV on highly active antiretroviral therapy","volume":"43","author":"Nasta","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: Single-center series of 25 cases and meta-analysis of 277 reported cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood.V122.21.1801.1801","article-title":"Plasmablastic Lymphoma Is Curable the HAART Era. A 10 Year Retrospective by the AIDS Malignancy Consortium (AMC)","volume":"122","author":"Noy","year":"2013","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood.V122.21.4310.4310","article-title":"Plasmablastic lymphoma: 28 patient single institution experience","volume":"122","author":"Patel","year":"2013","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.leukres.2011.06.023","article-title":"Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: A single institutional experience and literature review","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"Shipp","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor outcome of HIV-infected patients with plasmablastic lymphoma: Results from the German AIDS-related lymphoma cohort study","volume":"27","author":"Schommers","year":"2013","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/his.12640","article-title":"Epstein-Barr Virus-Positive Plasmacytoma in Immunocompetent Patients","volume":"67","author":"Loghavi","year":"2015","journal-title":"Histopathology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: Not in the mouth","volume":"11","author":"Castillo","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V126.23.811.811","article-title":"Randomized phase 2 open-label study of R-CHOP \u00b1 bortezomib in patients (Pts) with untreated non-germinal center B-cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): Results from the Pyramid trial (NCT00931918)","volume":"126","author":"Leonard","year":"2015","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2017.09.020","article-title":"Bortezomib in plasma-blastic lymphoma: A glimpse of hope for a hard-to-treat disease","volume":"62","author":"Mogollon","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428194.2015.1050666","article-title":"Bortezomib plus CHOP for the treatment of HIV-associated plasmablas-tic lymphoma: Clinical experience in three patients","volume":"57","author":"Gonzalez","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/10428194.2017.1416365","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: A retrospective analysis","volume":"59","author":"Dittus","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref_45","first-page":"10705","article-title":"Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: A systematic review and meta-analysis","volume":"8","author":"Fang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.3109\/10428194.2015.1016931","article-title":"Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric nonhuman immunodeficiency virus-associated plasmablastic lymphoma","volume":"56","author":"Carras","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_47","first-page":"2012","article-title":"Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone","volume":"30","author":"Bibas","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00277-016-2732-9","article-title":"Plasmablastic lymphoma: Successful management with CHOP and lenalidomide in resource constraint settings","volume":"95","author":"Yanamandra","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000455146","article-title":"A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy","volume":"40","author":"Schmit","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000504608","article-title":"Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma","volume":"43","author":"Ando","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"702593","DOI":"10.3389\/fimmu.2021.702593","article-title":"Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient with Tislelizumab and Lenalidomide","volume":"12","author":"Cheng","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.clml.2018.04.011","article-title":"Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient with Plasmablastic Lymphoma","volume":"18","author":"Marrero","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dittus, C., Miller, J.A., Wehbie, R., and Castillo, J.J. (Br. J. Haematol., 2022). Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma, Br. J. Haematol., online ahead of print.","DOI":"10.1111\/bjh.18228"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ccr3.3673","article-title":"Relapsed plasmablastic lymphoma in a HIV-negative patient: Pushing the envelope","volume":"9","author":"Kathrotiya","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2021-150800","article-title":"Daratumumab plus chemotherapy induces complete responses in a consecutive series of four patients with plasmablastic lymphoma","volume":"138","author":"Ricker","year":"2021","journal-title":"Blood"},{"key":"ref_57","unstructured":"(2021, June 07). Principal Investigator: Ferreri, A. Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patient\u2019s, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04915248."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3324\/haematol.2021.278841","article-title":"Plasmablastic lymphoma: One or more tumors?","volume":"106","author":"Pileri","year":"2021","journal-title":"Haematologica"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/7\/399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:41Z","timestamp":1760140361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/7\/399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["curroncol29070399"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29070399","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}